A Phase 1/2 Study of the Safety and Preliminary Activity of MYDICAR at a Dose of 2.5 x 10^13 DNase Resistant Particles (DRP) in Subjects With Advanced Heart Failure Divided Into 2 Phases: Phase 1 Open-label and Phase 2 Randomized, Double-blind, Placebo-controlled
Phase of Trial: Phase I/II
Latest Information Update: 03 Feb 2017
At a glance
- Drugs SERCA 2a gene therapy (Primary)
- Indications Heart failure
- Focus Adverse reactions
- Sponsors Celladon
- 07 Jun 2017 Biomarkers information updated
- 07 Jul 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
- 26 Apr 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.